Scope or classification is unclear
The product’s EU route, economic-operator roles or core functionality leave the CRA path open.
ConformVector supports established advisers whose US manufacturing clients sell connected industrial products into the European Union. Start with one anonymized client situation and determine whether a defined engineering assessment would close a real gap.
The product’s EU route, economic-operator roles or core functionality leave the CRA path open.
SBOMs, security requirements, test results and lifecycle decisions exist in separate places without product-level reasoning and traceability.
Article 14 ownership, escalation and clocks are not operational, or the security-support commitment does not match expected field life.
The starting point is one product family. Responsibilities and client communication are agreed before an introduction or engagement.
You continue the testing, product-safety, cybersecurity or market-access work your client engaged you to perform.
ConformVector documents scope and classification reasoning, evidence gaps, Article 14 readiness, support-period issues and a prioritized remediation path.
The manufacturer supplies available evidence, confirms assumptions and decides how identified gaps will be closed.
You identify a suitable case and introduce ConformVector. The manufacturer contracts directly for the defined Product Readiness Assessment.
You and ConformVector work with the same client under separate, coordinated scopes. Interfaces, meetings and outputs are agreed before work starts.
Where procurement or client preference calls for one lead provider, a subcontracted scope can be considered under a separate written agreement.
Client introductions, communication responsibilities, use of work products and any follow-on proposals are agreed in advance. Confidential product information is requested only after scope confirmation and, where required, an NDA.
The standard starting point is the fixed-scope CRA Product Readiness Assessment for one product family. The output is written for action: documented assumptions, a product-level evidence-gap view and a prioritized 90-day plan.
A nine-page field brief for US industrial manufacturers: Article 14 reporting, the 2027 evidence stack, classification, support period and a practical 90-day readiness sequence.